Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis.
Hyper-IgD and periodic fever syndrome (HIDS) is a hereditary autoinflammatory syndrome, characterized by recurrent inflammatory attacks. Treatment of HIDS is difficult. Recently, the IL-1ra analogue anakinra was reported to be successful in aborting the IgD inflammatory attacks in a vaccination model. We report a clinical case of spectacular reduction of febrile attacks in a severe HIDS patient.
Cailliez
M
M
AP-HM Timone-Enfants, F-13385, Marseilles Cedex 05, France.
Garaix
F
F
Rousset-Rouvière
C
C
Bruno
D
D
Kone-Paut
I
I
Sarles
J
J
Chabrol
B
B
Tsimaratos
M
M
D005334:Fever / Q000209:etiology / Q000628:therapy*; D006801:Humans; D006942:Hypergammaglobulinemia / Q000150:complications* / Q000628:therapy*; D007072:Immunoglobulin D / Q000737:chemistry; D007249:Inflammation; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D013577:Syndrome
D007072:Immunoglobulin D; D053590:Interleukin 1 Receptor Antagonist Protein